Assessment of high-sensitive methods for the detection of EGFR mutations in circulating free tumor DNA from NSCLC patients (Q38845760)

6 September 2017

Assessment of high-sensitive methods for the detection of EGFR mutations in circulating free tumor DNA from NSCLC patients (English)

1 reference

non-small-cell lung carcinoma

6 September 2017

1 reference

10

1 reference

6 September 2017

11

1 reference

6 September 2017

16

1 reference

6 September 2017

Anna Maria Rachiglio

7

0 references

Francesca Fenizia

Francesca Fenizia

2

0 references

Antonella De Luca

Antonella De Luca

15

0 references

Marc Denis

Marc G Denis

13

0 references

Raffaella Pasquale

Raffaella Pasquale

1

0 references

Gerardo Botti

12

Gerardo Botti

1 reference

6 September 2017

14

Alessandro Morabito

1 reference

6 September 2017

9

Agnese Montanino

1 reference

6 September 2017

8

Simona Bevilacqua

1 reference

PubMed ID

26249748

6 September 2017

Ana Cláudia C. Espósito

5

Claudia Esposito

1 reference

6 September 2017

6

Laura Forgione

1 reference

6 September 2017

Riziero Esposito Abate

3

1 reference

PubMed ID

26249748

6 September 2017

Alessandra Sacco

4

1 reference

6 September 2017

7 August 2015

1 reference

6 September 2017

1 reference

6 September 2017

16

1 reference

6 September 2017

1135-1148

1 reference

6 September 2017

10

1 reference

6 September 2017

1 reference

Genomics-driven oncology: framework for an emerging paradigm

21 January 2018

1 reference

Comprehensive molecular profiling of lung adenocarcinoma

21 January 2018

1 reference

Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer

21 January 2018

1 reference

Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients?

21 January 2018

1 reference

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

21 January 2018

1 reference

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

21 January 2018

1 reference

Liquid biopsies: genotyping circulating tumor DNA

21 January 2018

1 reference

Realizing the potential of plasma genotyping in an age of genotype-directed therapies.

21 January 2018

1 reference

Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status

21 January 2018

1 reference

First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.

21 January 2018

1 reference

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

21 January 2018

1 reference

Screening for epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp

21 January 2018

1 reference

Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer.

21 January 2018

1 reference

Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood

21 January 2018

1 reference

Detection of mutations in EGFR in circulating lung-cancer cells

21 January 2018

1 reference

Positron emission tomography and circulating tumor cells to monitor a dramatic response to gefitinib.

21 January 2018

1 reference

Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib

21 January 2018

1 reference

Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis

21 January 2018

1 reference

A noninvasive system for monitoring resistance to epidermal growth factor receptor tyrosine kinase inhibitors with plasma DNA.

21 January 2018

1 reference

Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA.

21 January 2018

1 reference

Molecular diagnostics and personalized medicine in oncology: Challenges and opportunities

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/PGS.15.45

1 reference

6 September 2017

1 reference

PubMed ID

26249748